开发一个风险预测的pyrotinib诱导的严重腹的nomogram模型
Qingqing Chen1, Guoding Huang2, Yaowen Xia3
1Department of Pharmacy, Hainan West Central Hospital, Danzhou, Hainan, China.
BMC cancer
|January 10, 2025
概括
这项研究确定了关键因素,如先前的不良反应和药物组合,可以预测服用pyrotinib的患者的严重腹. 一个经过验证的名录模型有助于临床医生识别高风险个体,以便及时进行干预.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 严重的腹是与pyrotinib治疗相关的显著不良事件.
- 识别预测因素对于管理pyrotinib治疗至关重要.
研究的目的:
- 为了确定影响皮罗丁尼布诱导严重腹的因素.
- 开发和验证这个不良事件的风险预测名ogram模型.
主要方法:
- 在两个机构中对226名用pyrotinib治疗的患者进行了回顾性分析.
- 后勤回归分析以确定独立的风险因素.
- 构建和外部验证一个名ogram模型.
主要成果:
- 确定的独立风险因素包括药物不良反应 (ADRs) 的病史,最初的pyrotinib剂量,与capecitabine的组合,血小板狭窄,AST水平,以及使用肠道微生物群调节药物.
- 诺莫格拉姆模型表现出良好的预测能力,AUC为0.794 (训练) 和0.863 (验证).
结论:
- 已经建立了一种经过验证的风险预测诺莫格拉姆模型,用于皮罗尼布诱导的严重腹.
- 这种模型可以帮助临床医生早期识别高风险患者,使得及时的临床决策和管理.
相关概念视频
Dosage Regimen Designs: Nomograms and Tabulations
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


